Skip to content
DataLookout
Menu

NCT06037252

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 19 versions: 18 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
  2. Minor Enrollment target: estimated 350 to confirmed 414
    • Primary completion date changed from estimate of Jan 2026 to Jan 8, 2026
    v19
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 42 to 40
    v18
  4. Minor Site details revised at 20 of 42 sitesv17
  5. Minor Site details revised at 20 of 42 sitesv16
Show 13 earlier versionsHide 13 earlier versions
  1. Minor Site contacts updated at 1 of 42 sitesv15
  2. Minor Site contacts updated at 1 of 42 sitesv14
  3. Minor Site details revised at 6 of 42 sitesv13
  4. Minor Site details revised at 35 of 42 sitesv12
  5. Notable Primary completion date: Dec 24, 2024 to Jan 2026
    • Study completion date: Sep 30, 2025 to Oct 2026
    v11
  6. Minor Study sites: 59 to 42v10
  7. Minor Site details revised at 1 of 59 sitesv9
  8. Minor Study sites revised (59)v8
  9. Minor Study sites: 45 to 59v6
  10. Minor Study sites: 12 to 45
    • Primary completion date: Jan 22, 2025 to Dec 24, 2024
    • Study completion date: Oct 29, 2025 to Sep 30, 2025
    v5
  11. Minor Study sites: 27 to 12
    • Primary completion date: Dec 24, 2024 to Jan 22, 2025
    • Study completion date: Sep 30, 2025 to Oct 29, 2025
    v4
  12. Minor Site details revised at 2 of 27 sitesv3
  13. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 49 to 27
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percent Change From Baseline in Body Weight
Timeframe: Baseline (Week 0), Week 44

Secondary (8)

Change from Baseline in HbA1c
Percent Change from Baseline in Body Weight
Absolute Change from Baseline in Body Weight
Change from Baseline in Body Mass Index (BMI)
Change from Baseline in BMI
Show 3 moreShow less
Change from Baseline in Waist Circumference
Percentage of Participants Achieving ≥15% Body Weight Reduction
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)

Arms and interventions

Tirzepatide High Dose 1Experimental

Participants will receive tirzepatide subcutaneously (SC).

Tirzepatide High Dose 2Experimental

Participants will receive tirzepatide SC.

TirzepatideActive comparator

Participants will receive tirzepatide SC.

PlaceboPlacebo comparator

Participants will receive placebo.

Drugs: Tirzepatide, Placebo

Sites

40 sites in 4 countries

United States 20, Turkey (Türkiye) 9, Mexico 6, Argentina 5